<DOC>
	<DOCNO>NCT02516397</DOCNO>
	<brief_summary>The purpose clinical trial evaluate safety efficacy food supplement OMNIA compare placebo reduce body fat mass 70 overweight subject 12 week treatment .</brief_summary>
	<brief_title>OMNIA Efficacy Body Fat Mass Reduction</brief_title>
	<detailed_description>Overweight obesity represent serious public health issue . These condition characterize abnormal excessive accumulation body fat mass relate increase risk develop chronic disease cardiovascular , diabetes , arthrosis certain kind cancer ( breast ; colon ) . It 's thus necessary find new product able counteract overweight obesity . Omnia food supplement base Phaseolus vulgaris extract . It pancreatic amylase inhibition property . In follow clinical trial , OMNIA administrate group overweight subject order evaluate efficacy reduce body fat mass . Its action compare placebo administer second group overweight volunteer modality OMNIA .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<criteria>25≤ BMI &lt; 30 kg/m2 excess fat mass food habit : 3 meal day glucides intake equivalent least 40 % daily energy ( i.e . : glucides intake meal ) Able give write verbal informed consent Affiliated beneficiary social security Weight loss/gain &gt; 2kg within preselection period ( 2 week ) Abnormal blood result V0 Physical activity ( sport ; lifestyle ) modification plan ongoing trial Severe pathologies/disorders ( bulimia ; anorexia ; diabetes ; cancer… ) emerge Pregnancy study Consent withdrawal Allergy Omnia observance &lt; 60 % Investigator promotor decision</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>body fat mass reduction</keyword>
</DOC>